STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- STAT+ Pharmalittle reported that GSK agreed to acquire Nuvalent for $10.6 billion, its largest oncology deal in years.
- STAT+ Pharmalittle noted that Nuvalent’s pipeline includes two molecules under FDA review for non‑small cell lung cancer.
- STAT+ Pharmalittle highlighted that Merck and Gilead’s experimental long‑acting HIV pill met its primary efficacy goal in Phase III trials, showing non‑inferiority to daily regimens.
- STAT+ Pharmalittle added that the HIV pill combines Merck’s islatravir with Gilead’s lenacapavir, offering a once‑weekly oral option that avoids injections.
- STAT+ Pharmalittle mentioned that GSK’s acquisition expands its oncology focus beyond gynecologic cancers and multiple myeloma into lung cancer.
Why it matters: The acquisition gives GSK a broader lung‑cancer portfolio, positioning it to capture upcoming FDA approvals and strengthening its competitive position, while the once‑weekly HIV pill adds a new oral regimen that replaces daily dosing and injections, expanding Merck and Gilead’s market options.
